![conference banner](/images/conference-banner.jpeg)
Abstract
Curcumin, a polyphenol isolated from the plant Curcuma longa, displays chemotherapeutic and chemopreventive effects in diverse cancers, including colorectal cancer. A mono-carbonyl analogue B63 was synthesized through several chemical modifications of the basic structure of curcumin to increase its biological activity and bioavailability. In vitro assays showed potent anti-proliferative effects of B63 on colon cancer cells (about 2 fold more effective than curcumin based on IC50). B63 treatment also induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 colon cancer cells. The pro-apoptotic proteins Bad and Bim were up-regulated, and cytochrome c release from the mitochondria into the cytosol was enhanced, resulting in pro-caspase-3 and PARP-1 cleavage. Furthermore, the anticancer activity of B63 was dependent on intracellular ROS from damaged mitochondrial function and induced endoplasmic reticulum (ER) stress. In vivo, 50 mg/kg of B63 inhibit tumor growth similarly to 100 mg/kg curcumin in a mouse xenograft model using SW620 cells. These results suggest that the curcumin derivative B63 has a greater anticancer capacity than the parent curcumin in colon cancer cells and that the necrotic and apoptotic effects of B63 are mediated by ROS resulting from ER stress and mitochondrial dysfunction.
Keywords: Colon cancer cells, curcumin, curcumin derivative, ER stress, mitochondrial dysfunction, ROS.
Current Cancer Drug Targets
Title:Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Volume: 14 Issue: 2
Author(s): Adi Zheng, Hao Li, Xun Wang, Zhihui Feng, Jie Xu, Ke Cao, Bo Zhou, Jing Wu and Jiankang Liu
Affiliation:
Keywords: Colon cancer cells, curcumin, curcumin derivative, ER stress, mitochondrial dysfunction, ROS.
Abstract: Curcumin, a polyphenol isolated from the plant Curcuma longa, displays chemotherapeutic and chemopreventive effects in diverse cancers, including colorectal cancer. A mono-carbonyl analogue B63 was synthesized through several chemical modifications of the basic structure of curcumin to increase its biological activity and bioavailability. In vitro assays showed potent anti-proliferative effects of B63 on colon cancer cells (about 2 fold more effective than curcumin based on IC50). B63 treatment also induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 colon cancer cells. The pro-apoptotic proteins Bad and Bim were up-regulated, and cytochrome c release from the mitochondria into the cytosol was enhanced, resulting in pro-caspase-3 and PARP-1 cleavage. Furthermore, the anticancer activity of B63 was dependent on intracellular ROS from damaged mitochondrial function and induced endoplasmic reticulum (ER) stress. In vivo, 50 mg/kg of B63 inhibit tumor growth similarly to 100 mg/kg curcumin in a mouse xenograft model using SW620 cells. These results suggest that the curcumin derivative B63 has a greater anticancer capacity than the parent curcumin in colon cancer cells and that the necrotic and apoptotic effects of B63 are mediated by ROS resulting from ER stress and mitochondrial dysfunction.
Export Options
About this article
Cite this article as:
Zheng Adi, Li Hao, Wang Xun, Feng Zhihui, Xu Jie, Cao Ke, Zhou Bo, Wu Jing and Liu Jiankang, Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction, Current Cancer Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1568009613666131126115444
DOI https://dx.doi.org/10.2174/1568009613666131126115444 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction of Linear B-Cell Epitopes with mRMR Feature Selection and Analysis
Current Bioinformatics Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism The Relationship Between the Serotonin Metabolism, Gut-Microbiota and the Gut-Brain Axis
Current Drug Metabolism The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation TP73, An Under-Appreciated Player in Non-Hodgkin Lymphoma Pathogenesis and Management
Current Molecular Medicine Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Comparative Evaluation of Colon Cancer Specific Antigen-2 Test and Chromocolonoscopy for Early Detection of Egyptian Patients with Colorectal Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia
Current Cancer Drug Targets Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Bioadhesive Nanoparticles as Potent Drug Delivery Carriers
Current Medicinal Chemistry Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine β-Aminocarbonyl Compounds: Chemistry and Biological Activities
Mini-Reviews in Organic Chemistry Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry
Current Medicinal Chemistry QSAR-Derived Choline Kinase Inhibitors: How Rational can Antiproliferative Drug Design Be?
Current Medicinal Chemistry MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Cancer Proteomics for Cellular Dysfunction: Insights and Trends
Current Pharmaceutical Design